Acasti Pharma Provides an Insight of Its Current Clinical Trials Results

Published: Dec 17, 2012

LAVAL, Quebec, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti") (TSX-V:APO), a Neptune Technologies & Bioressources Inc. ("Neptune") subsidiary, announces a clinical study update and announces the first ever human data of safety and efficacy of its patented prescription drug candidate CaPreĀ®.

Back to news